Increasingly well-preserved left ventricular function in hospital survivors with acute myocardial infarction - Effect of early and complete reperfusion strategy on left ventricular remodeling

Circulation Journal

Volumn 71, Issue 2, 2007, Pages 180-185

  Tani, Shigemasa ^a   Nagao, Ken ^a   Watanabe, Ikuyoshi ^b   Kikushima, Kimio ^b   Watanabe, Kazuhiro ^b   Anazawa, Takeo ^b   Kawamata, Hirofumi ^b   Tachibana, Eizo ^b   Matsumoto, Michiaki ^b   Kumabe, Takamichi ^b   Kanmatsuse, Katsuo ^b   Kushiro, Toshio ^b  

^a NIHON UNIVERSITY   (Japan)

^b NONE

Author keywords

Acute myocardial infarction; Coronary reperfusion therapy; Left ventricular remodeling

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVOR;

ACUTE DISEASE; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; THROMBOSIS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33846618837     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.180     Document Type: Article

References (39)

1. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Yano K. Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. Circ J 2005; 69: 83-88.
2. Ishikawa K, Kimura A, Taniwa T, Takenaka T, Hayashi T, Kanamasa K. Modification of treatment strategies over a period of 14 years has markedly reduced cardiac events among post-myocardial infarction patients. Circ J 2002; 66: 881-815.
3. Rosamond WD, Folsom AR, Chambless LE, Wang CH. Coronary heart disease trends in four United States communities: The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol 2001; 30(Suppl 1): S17-S22.
4. Robinson JG, Boland LL, McGovern PG, Folsom AR. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: The Minnesota heart survey. Circulation 2001; 104: 19-24.
5. Madsen JK, Grande P, Saunamaki K, Thayssen P, Kassis E, Eriksen U, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI): DANish trial in Acute Myocardial Infarction. Circulation 1997; 96: 748-755.
6. Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, Johnson AE, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999; 282: 341-348.
7. Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua M, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999; 33: 605-611.
8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
9. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283: 2941-2947.
10. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
11. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
12. Nagao K, Hayashi N, Kanmatsuse K, Kikuchi S, Ohuba T, Takahashi H, et al. An early and complete reperfusion strategy for acute myocardial infarction using fibrinolysis and subsequent transluminal therapy: The FAST trial. Circ J 2002; 66: 576-582.
13. Watanabe K, Nagao K, Watanabe I, Kanmatsuse K. Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: Analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial. Circ J 2004; 68: 280-285.
14. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, editor. Heart disease: A text book of cardiovascular medicine. Philadelphia: Saunders; 1992; 756-789.
15. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA Fr, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S from 1990 through 1999. J Am Coll Cardiol 2000; 36: 1954-1962.
16. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002; 106: 2351-2357.
17. Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun CC, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction: The Survival and Ventricular Enlargement Investigators. Circulation 1995; 92: 1101-1119.
18. Lundergan CF, Reiner JS, Ross AM. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: The case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. Am Heart J 2002; 144: 456-462.
19. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial (Plasminogen-activator Angioplasty Compatibility Trial). J Am Coll Cardiol 1999; 34: 1954-1962.
20. Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol 2001; 88: 831-846.
21. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988; 260: 2849-2858.
22. Bates ER, Califf RM, Stack RS, Aronson L, George BS, Candela RJ, et al. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: Influence of infarct location on arterial patency, left ventricular function and mortality J Am Coll Cardiol 1989; 13: 12-18.
23. Simoons ML, Arnold AE, Betriu A, de Bono DP, Col J, Dougherty FC, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197-203.
24. Bar FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, et al. Comparison of saruplase and alteplase in acute myocardial infarction: SESAM Study Group: The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997; 79: 727-732.
25. Bar F, Vainer J, Stevenhagen J, Neven K, Aalbregt R, Ophuis TO, et al. Ten-year experience with early angioplasty in 759 patients with acute myocardial infarction. J Am Coll Cardiol 2000; 36: 51-58.
26. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-536.
27. Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993; 72: 518-524.
28. Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Sex differences in early mortality of patients undergoing primary stenting for acute myocardial infarction. Circ J 2006; 70: 217-221.
29. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353: 2758-2768.
30. Wei JY, Markis JE, Malagold M, Grossman W. Time course of serum cardiac enzymes after intracoronary thrombolytic therapy: Creatine kinase, creatine kinase MB isozyme, lactate dehydrogenase, and serum glutamic-oxaloacetic transaminase. Arch Intern Med 1985; 145: 1596-1600.
31. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
32. Nakamura Y, Kawai C, Moss AJ, Raubertas RF, Brown MW, Kinoshita M, et al. Comparison between Japan and North America in the post-hospital course after recovery from an acute coronary event. Int J Cardiol 1996; 55: 245-254.
33. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: The Hisayama study. Stroke 2003; 34: 2349-2354.
34. Fukiyama K, Kimura Y, Wakugami K, Muratani H. Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res 2000; 23: 127-135.
35. Gheeraert PJ, Henriques JP, De Buyzere ML, Voet J, Calle P, Taeymans Y, et al. Out-of-hospital ventricular fibrillation in patients with acute myocardial infarction: Coronary angiographic determinants. J Am Coll Cardiol 2000; 35: 144-150.
36. Bjorklund E, Stenestrand U, Lindback J, Svensson L, Wallentin L, Lindahl B. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27: 1146-1152.
37. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial (The SAVE Investigators). N Engl J Med 1992; 327: 669-677.
38. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction: Comparison with nonischemic cardiomyopathy. Circ J 2005; 69: 143-149.
39. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.